Effect Of Myeloid-derived Suppressor Cells In The Occurring And Developing Hepatocellular Carcinoma

Objective:To detect the myeloid-derived suppressor cells level in the blood、spleen、bone marrow and tumour in the occurring and developing mice hepatocellular carcinoma and analysis its trend, Effect of the myeloid-derived suppressor cells in the occurring and developing mice hepatocellular carcinoma is discussed to offer theoretical foundation and methods of instruction for clinical test and Clinical Research.Methods:70C57BL/6J mice were randomized into three groups: experiment group(n=25), operation group(n=25) and control group(n=20). The experimental group and operation group were injected0.2-0.3ml mixed fluid (including mouse hepatocellular carcinoma cells [Hepa1-6]) into subcutaneous which led to tumors. The experimental group was measured tumor size and tested the myeloid inhibiting cell (MDSC) level in mice blood, spleen, bone marrow and tumor tissue in1st,3rd,7th,14th,21th day after injected. The operation group was cut most tumor tissue when the tumor diameter is more than or equal to lcm(about21th day after injected) and the myeloid inhibiting cell (MDSC) level was tested in mice blood, spleen, bone marrow and tumor tissue in1st,3rd,7th,14th,21th day after operation (residuals tumor diameter about equal to0.1cm). Control group was injected NS0.3ml and the myeloid inhibiting cell (MDSC) level be tested in mice blood, spleen, bone marrow and tumor tissue in1st,3rd,7th,14th,21th day after injected. Effect of myeloid-derived suppressor cells in the occurring and developing hepatocellular carcinoma was discussed with literature reviewed.Results:1. On the1st,3rd,7th,14th,21st day after tumor implantation,the proportion of blood MDSC was(2.15±1.33)%、(4.32±2.05)%、(9.44±2.93)%、(13.17±3.36)%、(17.62±4.09)%in experiment group; and (28.16±4.45)%、(21.32±3.96)%、(14.40±3.82)%、(10.83±3.60)%、(14.69±4.01)%in operation group。The proportion of blood MDSC in experiment group and operation group mice was significantly higher than control group (P<0.05) except the1st day of experiment group.2. On the1st,3rd,7th,14th,21st day after tumor implantation,the proportion of tumor MDSC [(1.40±0.67)%、(4.11±1.39)%、(6.73±2.14)%(13.56±3.18)%、(15.61±4.22)%]in experiment group was significantly lower than in operation group[(31.42±4.21)%、(35.25±7.54)%(21.07±4.89)、(18.38±4.15)%、(21.55±4.67)%、(p<0.05).3. On the3rd day after tumor implantation,the proportion of MDSC in bone marrow was up to about54%and then this trend was not obvious.4. On the7th day after tumor implantation,the proportion of MDSC in bone marrow was up to about7%and then this trend was slow down.Conclusion:1. The level of blood and tumor MDSC gradually was remarkably increasing with the growth of tumors, and both of them existed positive correlation. MDSC in bone marrow was significantly amplified in tumor-burdened mice and gathered at spleen and tumor.2. The level of MDSC at residual tumor tissues after operation is significantly higher than before. It may speed up the residual tumor growth and metastasis.3. The level of MDSC in blood was closely related with the growth of tumor in liver cancer tumor-burdened mice and it could be used to monitor recurrence after operation in hepatocellular carcinoma patients without hepatitis.